Lisinopril
- Generic Name
- Lisinopril
- Brand Names
- Prinivil, Qbrelis, Zestoretic, Zestril
- Drug Type
- Small Molecule
- Chemical Formula
- C21H31N3O5
- CAS Number
- 76547-98-3
- Unique Ingredient Identifier
- 7Q3P4BS2FD
- Background
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.
Lisinopril was granted FDA approval on 29 December 1987.
- Indication
Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.
- Associated Conditions
- Acute Myocardial Infarction (AMI), Cardiovascular Events, Congestive Heart Failure (CHF), Diabetic Nephropathy, Hypertension, Migraine
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
- Conditions
- Heart Failure, Congestive and Microalbuminuria
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1220
- Registration Number
- NCT00123903
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
- Conditions
- Diabetes Mellitus, Type IDiabetic Nephropathy
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2006-11-23
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 60
- Registration Number
- NCT00118976
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
The CLEVER Study - Coreg And Left Ventricular Mass Regression
- Conditions
- Hypertrophy, Left Ventricular
- Interventions
- First Posted Date
- 2005-04-14
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 287
- Registration Number
- NCT00108082
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
Genetics of Hypertension Associated Treatments (GenHAT)
- Conditions
- HypertensionHeart DiseasesCoronary DiseaseMyocardial InfarctionCardiovascular Diseases
- Interventions
- First Posted Date
- 2000-09-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Donna Arnett, 257-5678
- Target Recruit Count
- 37939
- Registration Number
- NCT00006294
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
- Conditions
- Myocardial InfarctionCoronary DiseaseMyocardial IschemiaHeart FailureHypercholesterolemiaDiabetes MellitusHypertensionCardiovascular DiseasesHeart Diseases
Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
- Conditions
- Diabetic Nephropathy
- Interventions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2018-03-07
- Target Recruit Count
- 160
- Registration Number
- NCT00004266
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.